<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 15, 2000
NEUROCRINE BIOSCIENCES, INC.
------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-22705 33-0525145
---------------------------- ------------------------ -----------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
10555 Science Center Drive, San Diego, California 92121
------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(858) 658-7600
------------------------------------------------------------
(Registrant's telephone number, including area code)
N/A
-----------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events.
On December 12, 2000, the registrant announced that it had expanded its
collaboration with Taisho Pharmaceutical Co., LTD., providing to Taisho the
exclusive rights to develop and commercialize the registrant's altered peptide
ligand product candidate for the treatment of diabetes in North America and
other countries outside of Europe and Asia. The full text of the registrant's
press release is set forth in Exhibit 99.1 attached hereto and is incorporated
in this report as if fully set forth herein. The amendment to the registrant's
license agreement with Taisho is set forth in Exhibit 99.2 hereto and is
incorporated in this report as if fully set forth herein. Confidential treatment
has been requested as to certain portions of this exhibit pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended. Confidential portions
will be filed separately with the Securities an Exchange Commission.
2
<PAGE>
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
The following exhibits are filed as part of this Report:
No. Exhibit
--- -------
99.1 Press Release dated December 12, 2000.
99.2** Amendment Number One dated November 30, 2000 to the License
Agreement dated July 21, 2000 between Taisho Pharmaceutical
Co., LTD. and the registrant.
** Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been designated by an
asterisk and has been filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as
amended, pursuant to an application for confidential treatment.
3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEUROCRINE BIOSCIENCES, INC.
(Registrant)
By: /s/ Gary A. Lyons
-----------------
Gary A. Lyons
President and Chief Executive Officer
Date: December 15, 2000
4
<PAGE>
EXHIBIT INDEX
No. Exhibit
--- -------
99.1 Press Release dated December 12, 2000.
99.2** Amendment Number One dated November 30, 2000 to the License Agreement
dated July 21, 2000 between Taisho Pharmaceutical Co., LTD. and the
registrant.
** Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been designated by an
asterisk and has been filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as
amended, pursuant to an application for confidential treatment.
5
